106 filings
DEFA14A
LABP
Landos Biopharma Inc
26 Mar 24
Additional proxy soliciting materials
8:50am
DEFA14A
LABP
Landos Biopharma Inc
25 Mar 24
Additional proxy soliciting materials
4:01pm
DEFA14A
LABP
Landos Biopharma Inc
25 Mar 24
Additional proxy soliciting materials
9:19am
8-K
LABP
Landos Biopharma Inc
25 Mar 24
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
8:54am
S-8
LABP
Landos Biopharma Inc
21 Mar 24
Registration of securities for employees
9:12am
8-K
c0q3bkw jtrkfy
21 Mar 24
Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results
8:08am
8-K
yf25qq1u1tnfw aca19z
4 Jan 24
Regulation FD Disclosure
8:05am
8-K
y1wsosfzjn k7dd38m
21 Nov 23
Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn’s and Colitis
8:08am
8-K
fs2rbla
9 Nov 23
Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results
8:08am
8-K
fx67alr kowce8wqkn
21 Sep 23
Departure of Directors or Certain Officers
8:00am
8-K
c5bsanmzqachto
14 Sep 23
Collaboration Will Focus on Defining the Effects Of NX-13 in Ulcerative Colitis Patient Derived Organoid Models
8:11am
8-K
zkkhjw5nf
9 Aug 23
Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results
8:12am
8-K
nr7551mwpscg
30 May 23
Departure of Directors or Certain Officers
4:53pm
8-K
8yi5lm8nc3bllae
25 May 23
Landos Biopharma Announces 1-for-10 Reverse Stock Split
4:19pm
8-K
yorq3v a5c
12 May 23
Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results
8:40am
ARS
i3au7e
19 Apr 23
Annual report to shareholders
8:05am